Eflornithine
- Generic Name
- Eflornithine
- Brand Names
- Vaniqa
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12F2N2O2
- CAS Number
- 70052-12-9
- Unique Ingredient Identifier
- ZQN1G5V6SR
- Background
Eflornithine is a prescription drug indicated in the treatment of facial hirsutism (excessive hair growth). Eflornithine hydrochloride cream for topical application is intended for use in women suffering from facial hirsutism and is sold by Allergan, Inc. under the brand name Vaniqa. Eflornithine for injection against sleeping sickness was manufactured by Sanofi Aventis and sold under the brand name Ornidyl in the USA. It is now discontinued. Eflornithine is on the World Health Organization's List of Essential Medicines.
- Indication
Eflornithine is indicated in the treatment of facial hirsutism (excessive hair growth).
- Associated Conditions
- Meningoencephalitic stage Trypanosoma brucei gambiense infection
- Associated Therapies
- Hair removal therapy
An Intermediate Expanded Use Trial of DFMO
- Conditions
- NeuroblastomaMedulloblastomaTypical Teratoid Rhabdoid TumorEmbryonal Tumor With Abundant Neuropil and True RosettesEpendymoblastomaMedulloepithelioma
- First Posted Date
- 2018-07-10
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Giselle Sholler
- Registration Number
- NCT03581240
- Locations
- 🇺🇸
Penn State Milton S. Hershey Medical Center and Children's Hospital, Hershey, Pennsylvania, United States
Oral AMXT 1501 Dicaprate in Combination With DFMO
- Conditions
- Advanced CancerCancerSolid CarcinomaSolid Tumor
- Interventions
- First Posted Date
- 2018-05-25
- Last Posted Date
- 2023-05-25
- Lead Sponsor
- Aminex Therapeutics, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT03536728
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Next Oncology - San Antonio, San Antonio, Texas, United States
🇺🇸Virginia Cancer Center, Fairfax, Virginia, United States
Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients
- Conditions
- Anaplastic AstrocytomaRecurrent Anaplastic Astrocytoma
- Interventions
- First Posted Date
- 2016-06-10
- Last Posted Date
- 2022-01-21
- Lead Sponsor
- Orbus Therapeutics, Inc.
- Target Recruit Count
- 343
- Registration Number
- NCT02796261
- Locations
- 🇨🇦
Montreal Neurological Institute and Hospital, Montréal, Quebec, Canada
🇫🇷Centre Jean Perrin, Clermont-Ferrand, France
🇫🇷Centre Georges François Leclerc, Dijon, France
Chemoprevention of Gastric Carcinogenesis
- Conditions
- Gastric CancerGastric Intestinal Metaplasia
- Interventions
- Other: Eflornithine placebo
- First Posted Date
- 2016-06-09
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 91
- Registration Number
- NCT02794428
- Locations
- 🇭🇳
Ministry of Health, Hospital de Occidente, Copán, Honduras
🇵🇷University of Puerto Rico, Comprehensive Cancer Center, San Juan, Puerto Rico
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
- Conditions
- Neuroblastoma
- Interventions
- First Posted Date
- 2015-09-24
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Giselle Sholler
- Target Recruit Count
- 500
- Registration Number
- NCT02559778
- Locations
- 🇺🇸
Penn State Milton S. Hershey Medical Center and Children's Hospital, Hershey, Pennsylvania, United States
🇺🇸St. Lukes, Boise, Idaho, United States
🇺🇸Connecticut Children's Hospital, Hartford, Connecticut, United States
Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission
- First Posted Date
- 2015-03-23
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Giselle Sholler
- Target Recruit Count
- 140
- Registration Number
- NCT02395666
- Locations
- 🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States
🇺🇸Rady Children's Hospital, San Diego, California, United States
🇺🇸Children's Hospital and Clinics on Minnesota, Minneapolis, Minnesota, United States
Study of Difluoromethylornithine (DFMO) in Combination With Bortezomib for Relapsed or Refractory Neuroblastoma
- First Posted Date
- 2014-05-15
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Giselle Sholler
- Target Recruit Count
- 16
- Registration Number
- NCT02139397
- Locations
- 🇺🇸
Connecticut Children's Hospital, Hartford, Connecticut, United States
🇺🇸Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸Helen DeVos Children's Hospital, Grand Rapids, Michigan, United States
N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan
- Conditions
- Neuroblastoma
- Interventions
- First Posted Date
- 2014-01-09
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- New Approaches to Neuroblastoma Therapy Consortium
- Target Recruit Count
- 30
- Registration Number
- NCT02030964
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇦🇺Sydney Childrens Hospital KCC, Randwick, Australia
🇺🇸Cook Children's Medical Center - Fort Worth, Fort Worth, Texas, United States
Treatment With Topical Eflornithin After Laser Treatment in Women With Facial Hirsutism
- First Posted Date
- 2013-03-26
- Last Posted Date
- 2013-12-02
- Lead Sponsor
- Bispebjerg Hospital
- Target Recruit Count
- 22
- Registration Number
- NCT01817894
- Locations
- 🇩🇰
Dermatological Dep Bispebjerg Hospital, Copenhagen NV, Copenhagen, Denmark
Pivotal Study of Fexinidazole for Human African Trypanosomiasis in Stage 2
- Conditions
- Human African Trypanosomiasis (HAT)Sleeping Sickness
- Interventions
- First Posted Date
- 2012-09-14
- Last Posted Date
- 2018-02-20
- Lead Sponsor
- Drugs for Neglected Diseases
- Target Recruit Count
- 394
- Registration Number
- NCT01685827
- Locations
- 🇨🇬
CRT (Centre de Réference et de Traitement) Dipumba, Dipumba general hospital, Mbuji Mayi, East Kasai, Congo
🇨🇬HGR ISANGI hospital, Isangi, Province Orientale, Congo
🇨🇬Masi Manimba Hospital, Masi Manimba, Bandundu - DRC, Congo
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.